Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Gets second patent for Alkindi from European Patent Office. Alkindi is a treatment for adrenal insufficiency, when the body's glands do not produce enough cortisol. "The patent provides in-market European protection until 2034 in all designated states of the European Patent Convention. The equivalent patents from the same family are already granted in the UK, Japan, Australia, Israel, South Africa, South Korea, China, India, Russia and the US," Diurnal says.
Current stock price: 72.00 pence, up 5.1% on Friday afternoon
Year-to-date change: up 26%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.